Mid- to Long-Term Outcome Results of the Ovation Stent Graft.


Journal

Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 07 05 2019
revised: 24 06 2019
accepted: 28 06 2019
pubmed: 20 9 2019
medline: 23 6 2020
entrez: 20 9 2019
Statut: ppublish

Résumé

To report mid-term to long-term outcome data for endovascular aortic repair using the Ovation stent-graft system (Endologix, Santa Rosa, CA) in a single university center. All patients treated with the Ovation stent graft between February 2012 and January 2019 were included. Patient demographics, anatomical and operative details, as well as follow-up data including complications, need for further interventions, and mortality were analyzed. A total of 74 patients (93% males; mean age, 74.5 years) were treated with the Ovation stent graft. The median maximal aortic diameter was 60 mm (range, 36-100). Sixty-two of 74 patients (83.8%) were considered to have a hostile neck. About 33% had a (reversed) conical neck, 59% had circumferential neck calcification (>50%), and 39% had significant neck thrombus (>50%). Technical success rate was 91.89%. Despite additional measures, 4 patients had a persistent type Ia endoleak on completion angiography, of which 3 disappeared on the first postoperative computed tomography angiography. Mean follow-up duration was 31.62 months ± 21.3 (range, 0-72.74 months). Twenty-four patients had a follow-up time of at least 36 months. Freedom from reintervention at 1, 2, 3, and 5 years was 92.7%, 90.8%, 80.1%, and 80.1%, respectively. Estimated freedom from mortality at 1, 2, 3, and 5 years was 96.8%, 95.0%, 87.3%, and 68.5%, respectively. No late type Ia or type III endoleak was detected during follow-up. No aneurysm-related mortality was seen. Our mid- to long-term experience with the Ovation stent-graft system demonstrates safe and durable results without late type Ia or type III endoleak.

Sections du résumé

BACKGROUND BACKGROUND
To report mid-term to long-term outcome data for endovascular aortic repair using the Ovation stent-graft system (Endologix, Santa Rosa, CA) in a single university center.
METHODS METHODS
All patients treated with the Ovation stent graft between February 2012 and January 2019 were included. Patient demographics, anatomical and operative details, as well as follow-up data including complications, need for further interventions, and mortality were analyzed.
RESULTS RESULTS
A total of 74 patients (93% males; mean age, 74.5 years) were treated with the Ovation stent graft. The median maximal aortic diameter was 60 mm (range, 36-100). Sixty-two of 74 patients (83.8%) were considered to have a hostile neck. About 33% had a (reversed) conical neck, 59% had circumferential neck calcification (>50%), and 39% had significant neck thrombus (>50%). Technical success rate was 91.89%. Despite additional measures, 4 patients had a persistent type Ia endoleak on completion angiography, of which 3 disappeared on the first postoperative computed tomography angiography. Mean follow-up duration was 31.62 months ± 21.3 (range, 0-72.74 months). Twenty-four patients had a follow-up time of at least 36 months. Freedom from reintervention at 1, 2, 3, and 5 years was 92.7%, 90.8%, 80.1%, and 80.1%, respectively. Estimated freedom from mortality at 1, 2, 3, and 5 years was 96.8%, 95.0%, 87.3%, and 68.5%, respectively. No late type Ia or type III endoleak was detected during follow-up. No aneurysm-related mortality was seen.
CONCLUSIONS CONCLUSIONS
Our mid- to long-term experience with the Ovation stent-graft system demonstrates safe and durable results without late type Ia or type III endoleak.

Identifiants

pubmed: 31536793
pii: S0890-5096(19)30718-6
doi: 10.1016/j.avsg.2019.06.045
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-135

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Hozan Mufty (H)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium. Electronic address: hozan.mufty@uzleuven.be.

Sabrina Houthoofd (S)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.

Kim Daenens (K)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.

Inge Fourneau (I)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.

Geert Maleux (G)

Department of Radiology, University Hospitals Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH